Morgan Stanley analyst Michael Ulz maintained a Buy rating on Kyverna Therapeutics, Inc. yesterday and set a price target of $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors that highlight the promising potential of Kyverna Therapeutics’ KYV-101. The recent data presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress showcased the clinical efficacy and safety of KYV-101 in treating progressive multiple sclerosis. The trials demonstrated an immune system reset in a significant number of patients, with improved disability scores and CAR-T cell penetration into the central nervous system.
Furthermore, the safety profile of KYV-101 was reinforced by the absence of high-grade cytokine release syndrome or neurotoxicity in the patients treated. The promising results from a compassionate-use case in rheumatoid arthritis also underscore the broader potential of KYV-101. With upcoming catalysts such as interim Phase 2 data expected soon, Ulz anticipates continued positive momentum for Kyverna Therapeutics, justifying the Buy rating.
In another report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
KYTX’s price has also changed dramatically for the past six months – from $2.350 to $6.440, which is a 174.04% increase.